Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSBR NASDAQ:INDP NASDAQ:LRMR NASDAQ:LYEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSBRChampions Oncology$5.85+1.6%$6.08$5.50▼$9.63$79.99M0.396,042 shs8,758 shsINDPIndaptus Therapeutics$2.85-5.9%$2.58$0.92▼$13.40$343.12M1.11617,261 shs92,752 shsLRMRLarimar Therapeutics$3.29+0.9%$3.62$2.71▼$6.42$338.66M0.832.94 million shs1.75 million shsLYELLyell Immunopharma$14.04-0.1%$15.89$9.02▼$45.00$327.84M-0.06233,176 shs213,764 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSBRChampions Oncology-4.08%-9.02%+3.54%-5.02%-24.71%INDPIndaptus Therapeutics-5.94%-6.86%-22.13%+78.13%-72.11%LRMRLarimar Therapeutics+0.92%+2.81%+3.79%-34.72%+4.78%LYELLyell Immunopharma-0.07%+10.12%+17.29%-35.54%+49.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSBRChampions Oncology$5.85+1.6%$6.08$5.50▼$9.63$79.99M0.396,042 shs8,758 shsINDPIndaptus Therapeutics$2.85-5.9%$2.58$0.92▼$13.40$343.12M1.11617,261 shs92,752 shsLRMRLarimar Therapeutics$3.29+0.9%$3.62$2.71▼$6.42$338.66M0.832.94 million shs1.75 million shsLYELLyell Immunopharma$14.04-0.1%$15.89$9.02▼$45.00$327.84M-0.06233,176 shs213,764 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSBRChampions Oncology-4.08%-9.02%+3.54%-5.02%-24.71%INDPIndaptus Therapeutics-5.94%-6.86%-22.13%+78.13%-72.11%LRMRLarimar Therapeutics+0.92%+2.81%+3.79%-34.72%+4.78%LYELLyell Immunopharma-0.07%+10.12%+17.29%-35.54%+49.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSBRChampions Oncology 1.00SellN/AN/AINDPIndaptus Therapeutics 1.00SellN/AN/ALRMRLarimar Therapeutics 3.09Buy$12.71286.45% UpsideLYELLyell Immunopharma 2.71Moderate Buy$43.00206.27% UpsideCurrent Analyst Ratings BreakdownLatest CSBR, INDP, LYEL, and LRMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2026LRMRLarimar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.006/30/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/30/2026LRMRLarimar Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026LRMRLarimar Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $5.006/15/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/15/2026LYELLyell Immunopharma Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$34.006/15/2026LYELLyell Immunopharma Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$44.006/9/2026LYELLyell Immunopharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/9/2026LYELLyell Immunopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.006/8/2026LYELLyell Immunopharma Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$44.006/3/2026LYELLyell Immunopharma Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$45.00(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSBRChampions Oncology$56.94M1.43$0.47 per share12.56$0.27 per share21.67INDPIndaptus TherapeuticsN/AN/AN/AN/A$1.40 per shareN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$0.94 per shareN/ALYELLyell Immunopharma$40K8,188.83N/AN/A$11.68 per share1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSBRChampions Oncology$4.70M-$0.16N/AN/AN/A-3.94%-57.31%-7.51%7/16/2026 (Estimated)INDPIndaptus Therapeutics-$20.85M-$15.40N/AN/AN/AN/A-1,030.07%-299.69%8/17/2026 (Estimated)LRMRLarimar Therapeutics-$165.67M-$2.06N/AN/AN/AN/A-134.14%-96.00%8/13/2026 (Estimated)LYELLyell Immunopharma-$274.45M-$13.80N/AN/AN/A-794,858.12%-85.71%-66.41%8/11/2026 (Estimated)Latest CSBR, INDP, LYEL, and LRMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/16/2026Q4 2026CSBRChampions Oncology-$0.05N/AN/AN/A$12.89 millionN/A5/15/2026Q1 2026INDPIndaptus Therapeutics-$1.87-$0.23+$1.64-$0.23N/AN/A5/14/2026Q1 2026LRMRLarimar Therapeutics-$0.53-$0.31+$0.22-$0.31N/AN/A5/6/2026Q1 2026LYELLyell Immunopharma-$1.10-$1.10N/A-$1.10$0.00 million$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCSBRChampions OncologyN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSBRChampions OncologyN/A0.980.98INDPIndaptus TherapeuticsN/A2.342.34LRMRLarimar TherapeuticsN/A4.294.29LYELLyell ImmunopharmaN/A7.237.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSBRChampions Oncology41.30%INDPIndaptus Therapeutics7.06%LRMRLarimar Therapeutics91.92%LYELLyell Immunopharma66.05%Insider OwnershipCompanyInsider OwnershipCSBRChampions Oncology46.40%INDPIndaptus Therapeutics23.60%LRMRLarimar Therapeutics4.50%LYELLyell Immunopharma6.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSBRChampions Oncology14313.89 million7.44 millionOptionableINDPIndaptus Therapeutics6113.24 million86.52 millionNot OptionableLRMRLarimar Therapeutics30103.88 million99.21 millionOptionableLYELLyell Immunopharma27023.33 million21.89 millionOptionableCSBR, INDP, LYEL, and LRMR HeadlinesRecent News About These CompaniesWall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a BetJuly 2, 2026 | zacks.comLyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual ...June 26, 2026 | enidnews.comELyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceJune 25, 2026 | globenewswire.comLyell Immunopharma Shareholders Back Governance at 2026 MeetingJune 15, 2026 | tipranks.comLyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European ...June 14, 2026 | finance.yahoo.comNew Safety Data and Translational Findings for Ronde-cel in Relapsed or Refractory Large B-Cell Lymphoma Announced by Lyell ImmunopharmaJune 12, 2026 | quiverquant.comQLyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 CongressJune 12, 2026 | globenewswire.comInsider Selling: Lyell Immunopharma (NASDAQ:LYEL) Insider Sells 1,977 Shares of StockJune 12, 2026 | insidertrades.comLyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comIs Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans?June 9, 2026 | finance.yahoo.comLyell Immunopharma Reports Significant Reduction in Grade ≥ 2 Diarrhea/Colitis in Phase 1 Trial of LYL273 for Metastatic Colorectal Cancer with GI ProphylaxisJune 8, 2026 | quiverquant.comQLyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 ExpansionJune 8, 2026 | globenewswire.comLyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 CongressJune 4, 2026 | markets.businessinsider.comLyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 CongressJune 4, 2026 | globenewswire.comLyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerJune 4, 2026 | zacks.comLyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026June 1, 2026 | globenewswire.comLyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum TranscriptMay 23, 2026 | seekingalpha.comLyell Immunopharma, Inc. (LYEL) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference TranscriptMay 22, 2026 | seekingalpha.comLyell Immunopharma COO Hill sells $1.5k in sharesMay 19, 2026 | investing.comDown 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)May 19, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSBR, INDP, LYEL, and LRMR Company DescriptionsChampions Oncology NASDAQ:CSBR$5.85 +0.09 (+1.56%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$5.88 +0.03 (+0.56%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Indaptus Therapeutics NASDAQ:INDP$2.85 -0.18 (-5.94%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$2.83 -0.02 (-0.70%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Larimar Therapeutics NASDAQ:LRMR$3.29 +0.03 (+0.92%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$3.30 +0.01 (+0.30%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Lyell Immunopharma NASDAQ:LYEL$14.04 -0.01 (-0.07%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$14.08 +0.04 (+0.28%) As of 07/6/2026 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
